TABLE 2.

Upper respiratory tract infections (URTI) and severe infections during systemic drug therapy of psoriatic arthritis

Substance	Targets	Risk for respiratory infections
Secukinumab, human mAb IgG1	IL‐17A	viral URTI are the most common adverse events
		with12.1 EAIR; risk for severe infections 1.9 EAIR 31
Ixekizumab, human mAb IgG	IL‐17A/ IL‐17AF	8.8 EAIR for URTI, severe infections 1.3 EAIR 32
Ustekinumab, human mAb IgG1K	IL‐12/IL‐23	all infections 100.5/patient years (PY), severe infection 0
PY33
Adalimumab, human mAb IgG1	TNFα	serious infections: 1.99 incidence rate 34
Etanercept, dimer chimeric of protein NFR2/p75 and Fc‐subunit of IgG1	TNFα‐receptor	serious infections: 2.58 incidence rate 34
Infliximab, chimeric mAb IgG1	TNFα	serious infections: 2.12 incidence rate 34
Golimumab, human mAb IgG1K	TNFα	serious infections: 0.4% incidence rate 35
Tofacitinib, JAK‐inhibitor	JAK1/JAK3	serious infections: 1.3–2.0 incidence rate 36
Apremilast, PDE4‐inhibitor	PDE4/TNFα	URTI 5.6–9.9%; serious infections 0.4–1.9% 37
Methotrexate, antifolate	dihydrofolate reductase inhibitor	serious infections: 3.01 incidence rate 34

Abbreviations: EAIR, exposure‐adjusted incidence rate per 100 patient‐years; mAb, monoclonal antibody; PY, patient years.